Close Menu
    Facebook X (Twitter) Instagram Pinterest YouTube LinkedIn TikTok
    TopBuzzMagazine.com
    Facebook X (Twitter) Instagram Pinterest YouTube LinkedIn TikTok
    • Home
    • Movies
    • Television
    • Music
    • Fashion
    • Books
    • Science
    • Technology
    • Cover Story
    • Contact
      • About
      • Amazon Disclaimer
      • Terms and Conditions
      • Privacy Policy
      • DMCA / Copyrights Disclaimer
    TopBuzzMagazine.com
    Home»Science»Herpes virus could soon be approved to treat severe skin cancer
    Science

    Herpes virus could soon be approved to treat severe skin cancer

    By AdminJuly 9, 2025
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Herpes virus could soon be approved to treat severe skin cancer


    Herpes virus could soon be approved to treat severe skin cancer

    Melanoma is a type of skin cancer that can spread elsewhere in the body

    SCIENCE PHOTO LIBRARY

    Despite many decades of effort and numerous human trials, only one virus that is designed to kill cancers has ever been approved by regulators in the US and Europe. But a second could get the green light at the end of the month, after getting good results for treating melanoma, a particularly serious type of skin cancer.

    A genetically modified herpes virus, called RP1, was injected into the tumours of 140 people with advanced melanoma for whom standard treatments had failed. The participants also took a drug called nivolumab, which is designed to boost the immune response to tumours.

    In 30 per cent of those treated, tumours shrank, including those that were not injected. In half of these cases, the tumours disappeared altogether.

    “Half the responders had complete responses, meaning the complete disappearance of all tumours,” says Gino Kim In at the University of Southern California. “We’re very excited about these results.” The other options for treating people at this stage don’t work as well and have more serious side effects, he says.

    A later-stage trial that will involve 400 people is now under way, but RP1 could be approved by the Food and Drug Administration (FDA) in the US for treating advanced melanoma in combination with nivolumab long before this trial finishes, In told New Scientist. “The FDA is supposed to give us a decision at the end of this month.”

    It has been known for more than a century that viral infections can sometimes help treat cancers, but deliberately infecting people with “wild” viruses is very risky. In the 1990s, biologists began genetically modifying viruses to try making them better at treating cancers, but unable to harm healthy cells.

    These viruses are designed to work in two ways. Firstly, by directly infecting cancer cells and killing them by bursting them apart. Secondly, by triggering an immune response that targets all cancerous cells, wherever they are in the body.

    For instance, a herpes simplex virus known as T-VEC, or Imlygic, was modified to make infected tumour cells release an immune-stimulating factor called GM-CSF, among other changes. In 2015, T-VEC was approved in the US and Europe for treating inoperable melanoma.

    But T-VEC is not widely used, says In, in part because it was only tested on and approved for injecting into tumours in the skin. Most people with advanced melanoma have deeper tumours, he says.

    With RP1, the decision was made to also try injecting it into deeper tumours. RP1 is a herpes simplex virus, like T-VEC, but has been improved in numerous ways. In particular, it makes tumour cells fuse with neighbouring cells, helping the virus to spread through tumours and boosting the immune response.

    There have been no directly comparable trials of T-VEC and RP1, but RP1 is more likely to induce shrinking of all tumours, not just the injected ones, In says. “That indicates a more powerful systemic effect.”

    Therefore, In expects RP1 to be much more widely used than T-VEC if it is approved. It will also provide a big boost to the whole idea of using cancer-killing viruses, he says. “I expect there will be a lot more interest.”

    Topics:

    View Original Source Here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Metformin may prevent severe morning sickness

    July 9, 2025

    Nanobody neutralizes deadly Nipah and Hendra viruses in lab tests

    July 8, 2025

    Melting glaciers could trigger volcanic eruptions around the globe, study finds

    July 8, 2025

    Vapour-sniffing drug detector tested at the US-Mexico border

    July 7, 2025

    Dark dwarfs lurking at the center of our galaxy might hint at the nature of dark matter

    July 7, 2025

    What did ancient Rome smell like? BO, rotting corpses and raw sewage for starters …

    July 6, 2025
    popular posts

    5 Things to Know about Climate Reparations

    How Amazon’s In-House First Aid Clinics Push Injured Employees to

    Portugal’s Ministry of Finance Eyeing a Capital Gains Tax for

    Kelli Giddish Set for SVU Encore: What Could It Mean

    The Fall/Winter Shoe Trends from NYFW Were Not What You’re

    ‘Wheel of Fortune’ Player Comes Brutally Close to $1 Million Prize — Fans React

    Sydney Sweeney and Her Fiancé Match in Coordinating Powder Blues

    Categories
    • Books (3,277)
    • Cover Story (4)
    • Events (18)
    • Fashion (2,441)
    • Interviews (43)
    • Movies (2,576)
    • Music (2,854)
    • News (155)
    • Politics (1)
    • Science (4,426)
    • Technology (2,569)
    • Television (3,299)
    • Uncategorized (932)
    Archives
    Facebook X (Twitter) Instagram Pinterest YouTube Reddit TikTok
    © 2025 Top Buzz Magazine. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
    Do not sell my personal information.
    Cookie SettingsAccept
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT